JP7434328B2 - シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 - Google Patents

シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 Download PDF

Info

Publication number
JP7434328B2
JP7434328B2 JP2021534820A JP2021534820A JP7434328B2 JP 7434328 B2 JP7434328 B2 JP 7434328B2 JP 2021534820 A JP2021534820 A JP 2021534820A JP 2021534820 A JP2021534820 A JP 2021534820A JP 7434328 B2 JP7434328 B2 JP 7434328B2
Authority
JP
Japan
Prior art keywords
antibody
seq
binding fragment
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021534820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535211A (ja
JP2021535211A5 (https=
Inventor
マリア ヘンドリック ラーツ、ジョセフ
ジェラルドゥス シルヴァノ シリヴィ、レナート
ロスマレン、ヨハネス ウィルヘルムス ジェラルドゥス ヴァン
Original Assignee
シトリル ビー．ヴィ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1813597.0A external-priority patent/GB201813597D0/en
Priority claimed from GBGB1900983.6A external-priority patent/GB201900983D0/en
Application filed by シトリル ビー．ヴィ． filed Critical シトリル ビー．ヴィ．
Publication of JP2021535211A publication Critical patent/JP2021535211A/ja
Publication of JP2021535211A5 publication Critical patent/JP2021535211A5/ja
Priority to JP2024016700A priority Critical patent/JP7835788B2/ja
Application granted granted Critical
Publication of JP7434328B2 publication Critical patent/JP7434328B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021534820A 2018-08-21 2019-08-20 シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 Active JP7434328B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024016700A JP7835788B2 (ja) 2018-08-21 2024-02-06 シトルリン化されたヒストン２ａ及び／又は４に結合する抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1813597.0 2018-08-21
GBGB1813597.0A GB201813597D0 (en) 2018-08-21 2018-08-21 Antibody
GB1900983.6 2019-01-24
GBGB1900983.6A GB201900983D0 (en) 2019-01-24 2019-01-24 Antibody
PCT/EP2019/072302 WO2020038963A1 (en) 2018-08-21 2019-08-20 Antibodies binding to citrullinated histone 2a and/or 4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024016700A Division JP7835788B2 (ja) 2018-08-21 2024-02-06 シトルリン化されたヒストン２ａ及び／又は４に結合する抗体

Publications (3)

Publication Number Publication Date
JP2021535211A JP2021535211A (ja) 2021-12-16
JP2021535211A5 JP2021535211A5 (https=) 2022-08-29
JP7434328B2 true JP7434328B2 (ja) 2024-02-20

Family

ID=67688785

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021534820A Active JP7434328B2 (ja) 2018-08-21 2019-08-20 シトルリン化されたヒストン２ａ及び／又は４に結合する抗体
JP2024016700A Active JP7835788B2 (ja) 2018-08-21 2024-02-06 シトルリン化されたヒストン２ａ及び／又は４に結合する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024016700A Active JP7835788B2 (ja) 2018-08-21 2024-02-06 シトルリン化されたヒストン２ａ及び／又は４に結合する抗体

Country Status (21)

Country Link
US (3) US20210395350A1 (https=)
EP (2) EP3841120B1 (https=)
JP (2) JP7434328B2 (https=)
KR (2) KR20250148711A (https=)
CN (2) CN120058926A (https=)
AU (3) AU2019326740B2 (https=)
CA (1) CA3110013A1 (https=)
DK (1) DK3841120T3 (https=)
ES (1) ES3048210T3 (https=)
FI (1) FI3841120T3 (https=)
HR (1) HRP20251346T1 (https=)
IL (2) IL280995B2 (https=)
LT (1) LT3841120T (https=)
MX (3) MX2025007881A (https=)
PT (1) PT3841120T (https=)
RS (1) RS67385B1 (https=)
SG (1) SG11202101652PA (https=)
SI (1) SI3841120T1 (https=)
SM (1) SMT202500388T1 (https=)
WO (1) WO2020038963A1 (https=)
ZA (1) ZA202101051B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
WO2021209465A1 (en) * 2020-04-14 2021-10-21 Universiteit Maastricht Peptide for the treatment of net-associated diseases
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
GB202012326D0 (en) 2020-08-07 2020-09-23 Citryll B V Diagnostic
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) * 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513374A (ja) 2009-12-10 2013-04-22 モディクエスト べー． フェー． シトルリン化エピトープに対する抗炎症剤
JP2018502903A (ja) 2014-12-11 2018-02-01 モディクエスト べー．フェー．Ｍｏｄｉｑｕｅｓｔ Ｂ．Ｖ． 特発性肺線維症の治療方法
JP2018523827A (ja) 2015-08-06 2018-08-23 ノビミューン エスアー Ｔｌｒ４依存性障害の診断および処置のための患者集団を特定するための方法および組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB201410520D0 (en) * 2014-06-12 2014-07-30 Univ London Queen Mary Antibody
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
CN117396221A (zh) * 2021-05-04 2024-01-12 奇特里尔私人有限公司 嗜酸性粒细胞陷阱的抑制
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513374A (ja) 2009-12-10 2013-04-22 モディクエスト べー． フェー． シトルリン化エピトープに対する抗炎症剤
JP2018502903A (ja) 2014-12-11 2018-02-01 モディクエスト べー．フェー．Ｍｏｄｉｑｕｅｓｔ Ｂ．Ｖ． 特発性肺線維症の治療方法
JP2018523827A (ja) 2015-08-06 2018-08-23 ノビミューン エスアー Ｔｌｒ４依存性障害の診断および処置のための患者集団を特定するための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATEL, C.N., et al.，"N+1 engineering of an aspartate isomerization hotspot in the complementarity-determing region of a monoclonal antibody."，JOURNAL OF PHARM. SCI.，2016年，Vol.105，pp.512-518，DOI: 10.1016/S0022-3549(15)00185-9

Also Published As

Publication number Publication date
IL322482A (en) 2025-09-01
CN112930356A (zh) 2021-06-08
IL280995B1 (en) 2025-09-01
US12590143B2 (en) 2026-03-31
JP2024059670A (ja) 2024-05-01
HRP20251346T1 (hr) 2025-12-19
EP4659807A3 (en) 2026-03-18
JP2021535211A (ja) 2021-12-16
IL280995A (en) 2021-04-29
AU2019326740B2 (en) 2025-11-27
LT3841120T (lt) 2025-11-10
ES3048210T3 (en) 2025-12-09
US20210395350A1 (en) 2021-12-23
RS67385B1 (sr) 2025-11-28
WO2020038963A1 (en) 2020-02-27
AU2026201302A1 (en) 2026-03-12
EP4659807A2 (en) 2025-12-10
MX2025007881A (es) 2025-08-01
ZA202101051B (en) 2022-08-31
KR102871821B1 (ko) 2025-10-16
SI3841120T1 (sl) 2025-12-31
CN112930356B (zh) 2025-03-21
FI3841120T3 (fi) 2025-11-03
AU2019326740A1 (en) 2021-03-18
KR20210056355A (ko) 2021-05-18
EP3841120A1 (en) 2021-06-30
DK3841120T3 (da) 2025-10-20
US20230183327A1 (en) 2023-06-15
KR20250148711A (ko) 2025-10-14
MX2021001902A (es) 2021-05-27
CA3110013A1 (en) 2020-02-27
IL280995B2 (en) 2026-01-01
CN120058926A (zh) 2025-05-30
US20210403543A1 (en) 2021-12-30
AU2026201303A1 (en) 2026-03-12
SG11202101652PA (en) 2021-03-30
PT3841120T (pt) 2025-10-20
EP3841120B1 (en) 2025-09-24
MX2025007882A (es) 2025-08-01
JP7835788B2 (ja) 2026-03-25
US11345750B2 (en) 2022-05-31
SMT202500388T1 (it) 2025-11-10

Similar Documents

Publication Publication Date Title
JP7434328B2 (ja) シトルリン化されたヒストン２ａ及び／又は４に結合する抗体
KR101947758B1 (ko) 포스포릴콜린에 대한 신규 항체
US20250084154A1 (en) Inhibition of eosinophilic traps
CN105518024B (zh) 人抗il-32抗体
HK40128527A (en) Antibodies binding to citrullinated histone 2a and/or 4
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
EA048367B1 (ru) Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4
EA053252B1 (ru) Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4
CN117396221A (zh) 嗜酸性粒细胞陷阱的抑制
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
WO2026012421A1 (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
HK40126807A (zh) Cnx抗原结合分子

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240207

R150 Certificate of patent or registration of utility model

Ref document number: 7434328

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150